ロード中...
Refractory hypotension due to Nivolumab-induced adrenal insufficiency
Nivolumab, a new immune checkpoint inhibitor that has been found to improve outcomes for patients with some advanced cancers, is being increasingly used. Immune checkpoint inhibitors can cause immune-related adverse events, including dermatitis, enterocolitis, hepatitis and hypophysitis, but adrenal...
保存先:
| 出版年: | Nagoya J Med Sci |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nagoya University
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5995729/ https://ncbi.nlm.nih.gov/pubmed/29915446 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18999/nagjms.80.2.285 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|